AzTrials
AzTrials

Nonalcoholic SteatohapatitisPhase 2NCT01703260

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

A Phase 2 study testing Roflumilast and Pioglitazone in people with Nonalcoholic Steatohapatitis, run by AstraZeneca at 4 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the effect of roflumilast and pioglitazone therapy on serum transaminase (ALT) levels in adults with Nonalcoholic SteatoHepatitis. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Nonalcoholic Steatohapatitis
What is being tested?
Roflumilast and Pioglitazone
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
20 participants
Where
4 sitesUnited States
Study dates
Jun 2013to Sep 2014
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • In the opinion of the investigator, the patient is capable of understanding and complying with protocol requirements.
  • The patient or, when applicable, the patient's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  • Has a historical diagnosis of NASH, established no more than 12 months prior to study entry based on histology (liver biopsy).
  • Has a NAFLD Activity Score (NAS) of ≥3, with a score of at least 1 in steatosis and lobular inflammation - the subcomponents of NAS. It is acceptable if the score for hepatocyte ballooning is "zero".
  • The subject has a MRI determined liver fat fraction of equal or higher than 7 percent.
  • The subject is female or male and aged 18 to 80 years, inclusive.
Show all 13Show fewer
  • A male who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 30 weeks after last dose.
  • A female of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose.
  • If taking Vitamin E and/or pentoxifylline, the subject has been receiving a stable dose for 6 months prior to randomization, started Vitamin E and/or pentoxifylline therapy prior to the qualifying liver biopsy, and agrees to maintain a stable dose throughout the study when possible.
  • Subject has an ALT level at Screening between 55 and 250 IU/L, inclusive, and between 60 and 250 IU/L at one other occasion during the 6 months prior to Randomization.
  • If taking a statin, should be on stable dose for 6 months prior to screening.
  • If taking angiotensin receptor blockers and fish oil, should be on a stable dose for at least 3 month prior to screening.
  • If diabetic, the subject is on a stable dose of metformin, dipeptidyl peptidase-4 inhibitor, sulfonylurea or insulin or a combination thereof for at least 3 months prior to Screening.

Who cannot join

  • The subject has a history of chronic liver disease other than NASH eg, chronic or acute hepatitis, Wilson's disease, alcoholic liver diseases or any other non-NASH active liver disease.
  • Subjects with liver cirrhosis (of any cause) or laboratory or clinical signs of functional liver failure
  • Clinically relevant abnormal laboratory values suggesting an undiagnosed disease other than NASH requiring further clinical evaluation (as assessed by the Investigator).
  • The subject has active cancer or a history of a malignant disease (except basal cell carcinoma) within 5 years prior to Screening or any history of bladder cancer.
  • Subject with a history of weight loss or weight gain of >10 pounds within 6 months prior to Screening.
  • Subject with a history of bariatric surgery within 5 years prior to Screening.
Show all 24Show fewer
  • The subject has received any investigational compound within 30 days prior to Screening or is currently participating in another clinical study.
  • The subject has a history of hypersensitivity or allergies to roflumilast or pioglitazone including any associated excipients.
  • The subject is required to take excluded medications.
  • The subject has taken oral or injectable glucocorticoids for longer than 7 days within 3 months prior to Screening.
  • The subject has poorly controlled Type 1 or Type 2 diabetes mellitus with an HbA1c ≥8.5 at Screening or per Investigator judgment.
  • The subject has hepatitis A, B or C.
  • The subject has severe immunological diseases (eg, known HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy) assessed at Screening.
  • The subject had a history of diabetic gastroparesis or history of gastric bypass surgery.
  • The subject had a history of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months prior to Screening.
  • The subject had New York Heart Association heart failure of Class (II-IV) regardless of therapy.
  • The subject had a diastolic blood pressure greater than 100 mm Hg or a systolic blood pressure of greater than 160 mm Hg (The mean of the 3 serial BP measurements will be used to determine subject eligibility).
  • The subject has presence or history of psychotic disorder that may be associated with suicidal thinking, ideation or behavior. These disorders include, but are not limited to, depression, psychosis, psychotic disorder, and schizophrenia. Subjects will be monitored by Columbia-Suicide Severity Rating Scales throughout the duration of the study.
  • The subject has a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic drinks per day for women or 3 alcoholic drinks per day for men. One drink is equivalent to a 12-ounce beer, a 4-ounce glass of wine, or a 1-ounce shot of hard liquor.) within 1 year prior to the Screening visit.
  • The subject has a hemoglobin <120 g/L for men and <100 g/L for women.
  • The subject has received pioglitazone or roflumilast in a previous clinical study or as a therapeutic agent within 1 year prior to screening.
  • If female, the subject is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  • The subject is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  • The subject has significant results from physical examinations or clinical laboratory results that, at the discretion of the investigator, would make it difficult to successfully manage and follow the subject according to the protocol.

Trial locations and contacts

4 sites in 1 country.

United States4 sites

  • Study site

    Annapolis, Maryland, 21401

  • Study site

    Baltimore, Maryland, 21202

  • Study site

    Coronado, California, 92118

  • Study site

    Coronado, California

Other trials in United States

About this study

Official title: A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects With Nonalcoholic SteatoHepatitis

The purpose of this study is to evaluate the effect of roflumilast and pioglitazone therapy on serum transaminase (ALT) levels in adults with Nonalcoholic SteatoHepatitis.

Read the detailed description

This proof of concept study will evaluate the effect of roflumilast and pioglitazone on transaminase levels and liver fat content.

Takeda has chosen not to continue this Study, however, randomized subjects were allowed to complete the study per protocol.

The decision to terminate the study is not related to any safety concerns with either of the study medications.

Being tested
Roflumilast, Pioglitazone, Placebo
Keywords
Drug therapy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RoflumilastDrug

    Also called Daxas, Daliresp

    Roflumilast dose

  • PioglitazoneDrug

    Also called Actos

    Pioglitazone dose

  • PlaceboDrug

    Pioglitazone placebo-matching dose

  • PlaceboDrug

    Roflumilast placebo-matching dose

Study groups in NCT01703260
Study groupRoleWhat they receive
Roflumilast + pioglitazoneExperimentalRoflumilast dose and pioglitazone dose, orally for up to 4 months
Receives: Drug: Roflumilast; Drug: Pioglitazone
RoflumilastExperimentalRoflumilast dose and pioglitazone matching-placebo dose orally for up to 4 months.
Receives: Drug: Roflumilast; Drug: Placebo
PioglitazoneExperimentalPioglitazone dose, orally and roflumilast matching-placebo dose, orally for up to 4 months
Receives: Drug: Pioglitazone; Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Amount of Serum Alanine Transaminase (ALT) at Baseline

    Measured: Baseline

  2. Percent Change From Baseline in Serum ALT at Month 4

    The percent change between the serum ALT value collected at Month 4 or final visit relative to baseline.

    Measured: Month 4

Secondary outcomes (4)

  1. Amount of Serum Aspartate Transaminase (AST) at Baseline

    Measured: Baseline

  2. Percent Change From Baseline in Serum AST at Month 4

    The percent change between the serum AST value collected at Month 4 or final visit relative to baseline.

    Measured: Month 4

  3. Liver Fat Content at Baseline

    Liver fat content was quantitatively measured by evaluating the percentage of proton density fat fraction (PDFF) from an abdominal magnetic resonance imaging (MRI). On the basis of Couinaud classification (a classification used to describe functional liver anatomy), the liver was divided into 8 segments: caudate, left superolateral, left inferolateral, left superomedial (4a), left inferomedial (4b), right anteroinferior, right posteroinferior, right posterosuperior and right anterosuperior.

    Measured: Baseline

  4. Change From Baseline in Liver Fat Content at Month 4

    Liver fat content was quantitatively measured by evaluating the percentage of PDFF from an abdominal MRI. On the basis of Couinaud classification (a classification used to describe functional liver anatomy), the liver was divided into 8 segments: caudate, left superolateral, left inferolateral, left superomedial (4a), left inferomedial (4b), right anteroinferior, right posteroinferior, right posterosuperior and right anterosuperior.

    Measured: Baseline and Month 4

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Oct 2012 (estimated)
  2. Study startJun 2013
  3. Primary completionSep 2014
  4. Study completionSep 2014

Why it stopped: Company decision; No safety or efficacy concerns (see detailed description)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01703260
Sponsor's protocol ID
ROF-NASH_205
Other IDs
U1111-1129-5051
Status last verified
Sep 2016
First submitted
2 Oct 2012
Last updated
1 Feb 2017
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Roflumilast and Pioglitazone in people with Nonalcoholic Steatohapatitis, run by AstraZeneca at 4 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 1 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Feb 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Amount of Serum Alanine Transaminase (ALT) at Baseline (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01703260.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Feb 2017.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in